AI assistant
Tempest Therapeutics, Inc. — Director's Dealing 2016
Jan 8, 2016
34632_dirs_2016-01-07_4b17cf4b-badd-4a19-87a7-3f1e5d062c91.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2016-01-05
Reporting Person: Stock Harald F. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-01-05 | Common Stock | A | 250000 | — | Acquired | 251228 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-01-05 | Stock Option (right to buy) | $9.42 | A | 250000 | Acquired | 2026-01-05 | Common Stock (250000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 15194 | Indirect |
Footnotes
F1: Each restricted stock unit ("RSU") represents the right to receive one share of common stock upon vesting. The RSU vests as to 25% of the shares on January 5, 2017 and as to an additional 6.25% of the shares each successive three-month period thereafter.
F2: Represents 1,228 shares of common stock and 250,000 RSUs.
F3: By SB Vermogensverwaltungs KG, a trust of which the reporting person is a majority shareholder and managing partner.
F4: The option vests as to 25% of the shares on January 5, 2017, and vests as to an additional 6.25% of the shares at the end of each successive three-month period thereafter.